Power Law company profile

ChemoCentryx

Biotech & Life Sciences · San Carlos, United States · Founded 1997 · IPO 2012 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$569M

Market cap · Apr/2026

Revenue

$90M

Latest reported FY

Investors

7 investors on ChemoCentryx's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series B+ 7 investors entered at this stage

HBM Healthcare Investments

OrbiMed

Patent intelligence

$524M patent portfolio · 156 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$524M

92.1% of market cap · 2.3× the top peer Ganymed Pharmaceuticals ($223M)

156 active patent families

Where ChemoCentryx innovates DiseaseAntagonistMolecular biologyArylPharmaceutical Substances

Above peer median on Legal, Strategic, Market, Economic, Technology

Quality vs same-sector peers

ChemoCentryx on the five Patsnap quality dimensions

ChemoCentryx in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where ChemoCentryx concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across ChemoCentryx and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See ChemoCentryx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo